USAdvisors Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

USAdvisors Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$43K	Buy	+10,000	New	+$58.5K	0.01%	146

Other funds holding SPRY

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

USAdvisors Wealth Management's SPRY Position: Q3 2026 in Review

USAdvisors Wealth Management opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2026: 10,000 shares worth $43K. The stake represents 0.01% of the portfolio and ranks #146 among its holdings.

17 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

USAdvisors Wealth Management held 10,000 shares of ARS Pharmaceuticals worth $43K as of Q3 2026.
ARS Pharmaceuticals was a new USAdvisors Wealth Management position in Q3 2026.
ARS Pharmaceuticals made up 0.01% of USAdvisors Wealth Management's portfolio in Q3 2026, its #146 holding.
17 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on USAdvisors Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.